AbbVie 2013 Annual Report Download - page 127
Download and view the complete annual report
Please find page 127 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124 -
125 -
126 -
127 -
128 -
129 -
130 -
131 -
132 -
133 -
134 -
135 -
136 -
137 -
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
 |
 |
17JAN201314181230
INFORMATION CONCERNING DIRECTOR NOMINEES (ITEM 1 ON PROXY CARD)
The board of directors consists of three classes with each class currently comprised of three
directors. Directors of one class are elected each year for a term of three years. The Class II directors
are presented for re-election to hold office until the expiration of their term at the 2017 annual
meeting of stockholders and until their successors are elected and qualified or until their earlier death
or resignation.
Directors are elected by stockholders if a majority of the votes cast are ‘‘for’’ a director’s reelection
at the Annual Meeting, excluding abstentions and broker non-votes. For more information on the
director majority vote standard, see AbbVie’s By-Laws as listed as an exhibit to AbbVie’s 2013 Annual
Report on SEC Form 10-K.
Class II—Directors Whose Terms Expire in 2014
Robert J. Alpern, M.D. Age 63
Ensign Professor of Medicine, Professor of Internal Medicine, and Dean of Yale
School of Medicine
Dr. Alpern has served as the Ensign Professor of Medicine, Professor of
Internal Medicine, and Dean of Yale School of Medicine since June 2004.
From July 1998 to June 2004, Dr. Alpern was the Dean of The University of
Texas Southwestern Medical Center. Dr. Alpern also serves as a director of
Abbott Laboratories and as a director on the Board of Yale—New Haven
Hospital. As the Ensign Professor of Medicine, Professor of Internal Medicine,
and Dean of Yale School of Medicine, Dean of The University of Texas
Southwestern Medical Center, and as a director on the Board of Yale—New
Haven Hospital, Dr. Alpern contributes valuable insights to the board through
his medical and scientific expertise and his knowledge of the health care
environment and the scientific nature of AbbVie’s key research and
development initiatives.
4